Key Takeaways
- Health Canada is reviewing nine submissions for generic versions of popular weight loss medications, including semaglutide, the active ingredient in Ozempic and Wegovy.
- The medications, known as glucagon-like peptide-1 (GLP-1) therapies, mimic a natural gut hormone to help control blood sugar levels, slow digestion, and increase feelings of fullness.
- The generic versions could bring down the price of the medications, currently costing between $200 to $400 a month, to around $100 to $150 a month.
- The approval of generic versions could increase accessibility for patients, particularly those without insurance coverage, and could be a significant tool in obesity management.
Introduction to Generic Versions of Semaglutide
Health Canada is currently reviewing nine submissions for generic versions of popular weight loss medications, including semaglutide, the active ingredient in Novo Nordisk’s injectable prescription drugs Ozempic and Wegovy. The medications, known as glucagon-like peptide-1 (GLP-1) therapies, mimic a natural gut hormone to help control blood sugar levels, slow digestion, and increase feelings of fullness. Common side effects of semaglutide can include nausea, vomiting, diarrhea, and stomach pain, as well as fatigue, constipation, and headaches. Canada is the only country where Novo Nordisk allowed the patent for its semaglutide drugs to expire, paving the way for "regulatory exclusivity" to end on January 4, and potentially making it the first country to offer a cheaper version of Ozempic and Wegovy to people with prescriptions.
What are Generic Versions?
Generic versions of medications are pharmaceutically equivalent to brand name drugs, according to Health Canada. The regulator examines data provided by companies to ensure that the submission meets its criteria for safety, quality, and effectiveness before authorizing any drug, whether it’s a brand name or generic version. Evaluating generic semaglutide drugs is more complex than many other medication approvals, as semaglutide was originally developed using biological processes, but the generic versions can be made using more simple chemical means. When a patent expires, other companies are allowed to make copies of the drug, which can lower the price, as these companies don’t have to spend as much money studying the medication.
Pricing and Availability
Pricing depends on several factors, including whether a prescription medication is available in a branded formulation, how many cheaper generic versions are available on the market, the formation of the drug, and the dosing. Given these challenges, experts don’t expect the cheaper versions to be immediately available. Mina Tadrous, an associate professor at the Leslie Dan Faculty of Pharmacy at the University of Toronto, suggests that summer would be a more likely timeframe for the approval of generic versions. The approval of generic versions could bring down the price of the medications, currently costing between $200 to $400 a month, to around $100 to $150 a month, making them more accessible to patients.
Impact on Patients
Canadians taking GLP-1 medications for weight loss pay a significant amount out of pocket, as many Canadian insurance companies don’t cover the medications for obesity. Having generics that might significantly reduce the price is welcome, particularly for patients who don’t have insurance coverage and cannot afford these medications. Dr. Sanjeev Sockalingam, scientific director of Obesity Canada, notes that accessibility is another consideration, and having more affordable options could be a significant tool in obesity management, given that obesity affects one in three Canadians.
Companies Applying for Generic Submissions
The list of companies applying to have generic submissions reviewed by Health Canada includes Sandoz Canada, Apotex, Teva Canada, Taro Pharmaceuticals, and Aspen Pharmacare Canada. The remaining companies aren’t named, as their submissions were received before April 1, 2023, when Health Canada’s policy changed to require sponsors to be named. The approval of generic versions of semaglutide could increase competition in the market, driving down prices and making the medications more accessible to patients.
Conclusion
In conclusion, the review of generic versions of semaglutide by Health Canada could have a significant impact on the accessibility and affordability of weight loss medications for Canadians. The approval of generic versions could bring down the price of the medications, making them more accessible to patients, particularly those without insurance coverage. As the regulator continues to review the submissions, patients and healthcare providers await the potential approval of more affordable options for obesity management.